Report on collaborative R&D in drug development released

Global health science marketing and communications firm, SCORR Marketing, has released a new study, in partnership with Applied Clinical Trials, evaluating the extent to which collaborations occur in the life sciences what influences these collaborations.

“To fight the growing complexity and costs of drug development, drug sponsors are turning to a variety of strategies, one of which is collaborating on research and development (R&D),” said Anne-Marie Hess, senior strategic advisor at SCORR. “To help the industry better understand this strategy, we gathered information about attitudes toward collaborative R&D, its benefits and risks, which groups participate in such collaborations and why some partnerships are more productive than others.”

The Collaborative R&D Survey Report also features information on why the industry believes R&D collaborations are increasing, which stakeholders may be more receptive to these partnerships and the types of medicines, therapeutic areas and medical devices will see more R&D collaborations in the near future.

“Shared expertise and more efficient resource allocation were the two greatest perceived benefits of collaborative R&D,” said Lisa Henderson, group content director, Applied Clinical Trials, and pharmaceutical executive at UBM Americas. “What surprised us throughout the survey was the large discrepancy we found in some areas based on the respondents’ demographics — where their company was headquartered, the size of their company and their particular field.”